CCND2 and cervical carcinoma: Overall, our findings shed new insights on the mechanisms of CDDP resistance and purport possible clinical application of targeting the OTUD6B-AS1/miR-206/CCND2 pathway as a promising way to reverse CDDP resistance and improve the prognosis of patients with cervical cancer.